CN104922677A - 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 - Google Patents
一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 Download PDFInfo
- Publication number
- CN104922677A CN104922677A CN201510275098.6A CN201510275098A CN104922677A CN 104922677 A CN104922677 A CN 104922677A CN 201510275098 A CN201510275098 A CN 201510275098A CN 104922677 A CN104922677 A CN 104922677A
- Authority
- CN
- China
- Prior art keywords
- parts
- cepharanthine
- hydrochloride
- pharmaceutical composition
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 title claims abstract description 65
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 title claims abstract description 65
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 201000002364 leukopenia Diseases 0.000 title abstract description 5
- 231100001022 leukopenia Toxicity 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title abstract description 4
- 239000000890 drug combination Substances 0.000 title abstract 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 84
- 239000007924 injection Substances 0.000 claims abstract description 33
- 238000002347 injection Methods 0.000 claims abstract description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 27
- 229930195725 Mannitol Natural products 0.000 claims abstract description 27
- 239000000594 mannitol Substances 0.000 claims abstract description 27
- 235000010355 mannitol Nutrition 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 31
- 239000008103 glucose Substances 0.000 claims description 27
- YDDGBJGRSLHCOE-UHFFFAOYSA-N Cepharantine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2C1NCC3 YDDGBJGRSLHCOE-UHFFFAOYSA-N 0.000 claims description 26
- YVPXVXANRNDGTA-VMPREFPWSA-N cepharantine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-VMPREFPWSA-N 0.000 claims description 26
- 239000008176 lyophilized powder Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 230000000610 leukopenic effect Effects 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 abstract description 4
- 230000007012 clinical effect Effects 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 description 1
- 241001289435 Astragalus brachycalyx Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 剂量(ml/kg) | WBC(109/L) |
正常对照组 | 20 | 6.21±1.59 |
模型对照组 | 20 | 1.67±0.88 |
阳性对照组 | 20 | 2.79±0.58 |
实施例1组 | 20 | 4.31±0.24 |
实施例2组 | 20 | 4.10±0.66 |
实施例3组 | 20 | 4.08±0.75 |
实施例4组 | 20 | 3.84±0.31 |
实施例5组 | 20 | 3.74±0.78 |
对比例1组 | 20 | 3.10±0.11 |
对比例2组 | 20 | 2.98±0.89 |
对比例3组 | 20 | 2.87±0.24 |
对比例4组 | 20 | 2.08±0.47 |
对比例5组 | 20 | 2.11±0.78 |
对比例6组 | 20 | 1.96±0.48 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510275098.6A CN104922677B (zh) | 2015-05-27 | 2015-05-27 | 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510275098.6A CN104922677B (zh) | 2015-05-27 | 2015-05-27 | 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104922677A true CN104922677A (zh) | 2015-09-23 |
CN104922677B CN104922677B (zh) | 2018-06-12 |
Family
ID=54110319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510275098.6A Active CN104922677B (zh) | 2015-05-27 | 2015-05-27 | 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104922677B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111228269A (zh) * | 2020-04-02 | 2020-06-05 | 广州暨南生物医药研究开发基地有限公司 | 千金藤碱及其盐作为铁死亡诱导剂在制备抗肿瘤药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1875945A (zh) * | 2006-05-09 | 2006-12-13 | 广州暨南生物医药研究开发基地有限公司 | 盐酸千金藤碱冻干粉针剂及其制备方法 |
CN103083261A (zh) * | 2013-02-18 | 2013-05-08 | 青岛正大海尔制药有限公司 | 藻酸双酯钠冻干粉针 |
-
2015
- 2015-05-27 CN CN201510275098.6A patent/CN104922677B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1875945A (zh) * | 2006-05-09 | 2006-12-13 | 广州暨南生物医药研究开发基地有限公司 | 盐酸千金藤碱冻干粉针剂及其制备方法 |
CN103083261A (zh) * | 2013-02-18 | 2013-05-08 | 青岛正大海尔制药有限公司 | 藻酸双酯钠冻干粉针 |
Non-Patent Citations (1)
Title |
---|
傅超美等: "《药用辅料学》", 31 October 2008, 中国中医药出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111228269A (zh) * | 2020-04-02 | 2020-06-05 | 广州暨南生物医药研究开发基地有限公司 | 千金藤碱及其盐作为铁死亡诱导剂在制备抗肿瘤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104922677B (zh) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103494780B (zh) | 一种注射用加米霉素组合物冻干粉及制备方法 | |
CN103655599B (zh) | 多糖组合物及应用、含其的药物制剂 | |
CN104922677A (zh) | 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用 | |
CN109481459B (zh) | 一种复方电解质葡萄糖注射液及其制备方法 | |
CN102846732B (zh) | 一种用于治疗乳腺增生的中药组合物及其制备方法 | |
CN107266599B (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
CN104306401A (zh) | 一种升高白细胞作用的梅花鹿鹿脾提取物的制备及用途 | |
CN103830255A (zh) | 芍药苷在制备治疗脑血管疾病的药物中的应用 | |
CN109260205B (zh) | 一种汉防己甲素在制备抗糖尿病合并高血压药物中的应用 | |
CN102757471B (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN102274194B (zh) | 一种含托烷司琼化合物的药物组合物及其制备方法 | |
CN114652675A (zh) | 一种盐酸乌拉地尔注射液的制备方法 | |
CN1660347A (zh) | 银黄组合物、含有银黄组合物的口服和注射制剂及其制备方法和用途 | |
CN101301284B (zh) | 大黄酸或其盐在制备治疗慢性肾炎或慢性肾功能衰竭药物中的应用 | |
CN110693822A (zh) | 一种布洛芬注射液及制备方法 | |
CN105434432B (zh) | N-羟基邻苯二甲酰亚胺类化合物在制备抗肿瘤药物中的应用 | |
CN104434788A (zh) | 一种阿替洛尔注射液的制备方法 | |
CN103040822B (zh) | 一种含有苦参素化合物的药物组合物及其制备方法 | |
CN110833553A (zh) | 吡唑并嘧啶衍生物在治疗Arthus反应的用途 | |
CN101502558B (zh) | 环糊精组合物制备黄芪总皂苷注射液的方法 | |
CN113893280B (zh) | 一种治疗失眠的联合用药物及其制备方法 | |
CN110357881B (zh) | 苦木中β-卡波林型生物碱的提取工艺和应用 | |
CN115671219B (zh) | 一种治疗痛风的中药组合物及其制备方法和应用 | |
CN106074719A (zh) | 莲子心提取物在制备治疗肺纤维化药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151111 Address after: 510520, Guangzhou, Guangdong province Tianhe District hi tech Road, No. 32, No. 34, block B1, South Building, 4 floor, East Applicant after: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: South 5 building 510632 Guangdong city of Guangzhou province Tianhe District Whampoa Road West, No. 601 Jinan University College of life science and technology Applicant before: Guangzhou Jinan Biomedical Research and Development center |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 510032 -29, No. 339 Heng Jiang Road, Conghua suburb street, Guangzhou, Guangdong (first floor, A factory). Patentee after: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: 510520 east 4 floor, B1 south tower, 32 and 34, Tianhe District high tech Road, Guangzhou, Guangdong. Patentee before: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510320 unit 403a, 4th floor, production area, No. 1, helix 4th Road, International Biological Island, Huangpu District, Guangzhou, Guangdong Province Patentee after: Guangzhou kangqilai precision medical technology Co.,Ltd. Address before: 510032 -29, No. 339 Heng Jiang Road, Conghua suburb street, Guangzhou, Guangdong (first floor, A factory). Patentee before: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220713 Address after: 510610 room 4105, No. 365, Tianhe North Road, Tianhe District, Guangzhou, Guangdong Province (office only) Patentee after: Guangzhou Shaobo Holding Group Co.,Ltd. Address before: 510320 unit 403a, 4th floor, production area, No. 1, helix 4th Road, International Biological Island, Huangpu District, Guangzhou, Guangdong Province Patentee before: Guangzhou kangqilai precision medical technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221008 Address after: 510610 room 4105, No. 365, Tianhe North Road, Tianhe District, Guangzhou, Guangdong Province (office only) Patentee after: Guangzhou Shaobo Holding Group Co.,Ltd. Patentee after: Guangzhou Shaobo Health Technology Co.,Ltd. Address before: 510610 room 4105, No. 365, Tianhe North Road, Tianhe District, Guangzhou, Guangdong Province (office only) Patentee before: Guangzhou Shaobo Holding Group Co.,Ltd. |